Trials / Conditions / Refractory Primary Malignant Central Nervous System Neoplasm
Refractory Primary Malignant Central Nervous System Neoplasm
4 registered clinical trials studyying Refractory Primary Malignant Central Nervous System Neoplasm — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Active Not Recruiting | Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Di NCT05768880 | Seattle Children's Hospital | Phase 1 |
| Recruiting | CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma NCT04870944 | Children's Oncology Group | Phase 1 / Phase 2 |
| Active Not Recruiting | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders Wi NCT03698994 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wi NCT02867592 | National Cancer Institute (NCI) | Phase 2 |